Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs 'Discontinuous' Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM)

Autor: Joshua Epstein, John Crowley, Bart Barlogie, Klaus Hollmig, Elias Anaissie, Teresa Milner, Frits van Rhee, Guido Tricot, Erik Rasmussen, Maurizio Zangari, John D. Shaughnessy
Rok vydání: 2005
Předmět:
Zdroj: Blood. 106:1153-1153
ISSN: 1528-0020
0006-4971
Popis: Background: The extension of overall survival (OS) in MM has been partly linked to increasing CR rates especially with high-dose melphalan. Data bases of TT1 and TT2 were examined to determine whether 5-yr Rc was key to prolonged OS. Patients and Methods: TT1 enrolled 231 and TT2 668 patients (median follow-up, 4 years). Pre-study characteristics of Rc vs Rd patients surviving >= 5yrs were compared. Furthermore, subsequent OS was examined in the context of pre-treatment variables, TT2 vs TT1 and Rc vs Rd. Only those Rd patients who were event-free (CR or PR) at least 1 year prior to the 5-yr landmark were included in this analysis. Results: Among 231 TT1 + TT2 patients surviving >= 5yrs, more TT2 patients were Rc compared to Rd (60% vs 19%, p Conclusion: 5-yr Rc appears to be an important prerequisite for prolonged subsequent OS, which could be significantly increased with better therapy (TT2 vs TT1). Post-5-yr favorable survival predictors included several laboratory data at 5yrs, especially absence of CA. Overall Survival from 5 Years Post Enrollment by Remission Status at 5 Years (Interrupted vs Continuous Remisssion) Overall Survival from 5 Years Post Enrollment by Remission Status at 5 Years (Interrupted vs Continuous Remisssion)
Databáze: OpenAIRE
Externí odkaz: